SCHEMBL4078326

SCHEMBL4078326

Cc1[nH]c(=O)c2cc(F)ccc2c1C1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.48
TNKS O95271 4/20 0.46
TNKS2 Q9H2K2 4/20 0.46
KCNH2 Q12809 4/20 0.46
SLC6A2 P23975 6/20 0.40
SLC6A4 P31645 6/20 0.40
SLC6A3 Q01959 5/20 0.40
HTR1A P08908 3/20 0.40
TLR9 Q9NR96 1/20 0.39
TLR8 Q9NR97 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
CCR3 P51677 1/20 0.39
HTR6 P50406 3/20 0.39
PGR P06401 1/20 0.38
AR P10275 1/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4068442 0.92 KCNH2 (0.46) PARP1TNKSTNKS2KCNH2SLC6A2
SCHEMBL4069841 0.86 HTR2C (0.42) PARP1TNKSTNKS2KCNH2SLC6A2
SCHEMBL4074502 0.84 TNKS (0.47) PARP1TNKSTNKS2CCR3HTR6
SCHEMBL4078132 0.84 PARP1 (0.44) PARP1TNKSTNKS2KCNH2HTR1A
SCHEMBL4077380 0.83 HTR2C (0.51) PARP1KCNH2TLR9TLR8TLR7
SCHEMBL4068281 0.81 CCR3 (0.49) PARP1SLC6A4CCR3DRD2
SCHEMBL4079404 0.80 PARP1 (0.43) PARP1TNKSTNKS2KCNH2SLC6A4
SCHEMBL4079214 0.79 PARP1 (0.40) PARP1KCNH2PGRARDRD2
SCHEMBL4078598 0.78 CCR3 (0.52) PARP1KCNH2SLC6A4CCR3DRD2
SCHEMBL4075963 0.78 CCR3 (0.46) PARP1SLC6A4CCR3DRD2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 PARP1 1/4885TNKS 127/4885TNKS2 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.